Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) EBIT (2016 - 2025)

Avalo Therapeutics filings provide 12 years of EBIT readings, the most recent being -$19.7 million for Q4 2025.

  • On a quarterly basis, EBIT fell 48.31% to -$19.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$72.9 million, a 6.44% decrease, with the full-year FY2025 number at -$72.9 million, down 6.44% from a year prior.
  • EBIT hit -$19.7 million in Q4 2025 for Avalo Therapeutics, down from -$19.2 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $4.1 million in Q3 2022 to a low of -$32.8 million in Q1 2024.
  • Median EBIT over the past 5 years was -$14.0 million (2024), compared with a mean of -$14.4 million.
  • Biggest five-year swings in EBIT: surged 124.87% in 2022 and later plummeted 272.69% in 2024.
  • Avalo Therapeutics' EBIT stood at -$18.0 million in 2021, then soared by 50.7% to -$8.9 million in 2022, then grew by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 48.31% to -$19.7 million in 2025.
  • The last three reported values for EBIT were -$19.7 million (Q4 2025), -$19.2 million (Q3 2025), and -$19.3 million (Q2 2025) per Business Quant data.